Evaluation of hepatitis C treatment-as-prevention within Australian prisons (SToP-C): a prospective cohort study

In subjects at risk of HCV primary infection or re-infection, direct-acting antiviral treatment scale-up reduced HCV incidence (8.31 vs 4.35 per 100 person-years in the pre-treatment and post treatment scale-up period respectively; IRR 0.52; 95% CI 0.36–0.78; p=0.0007).

Source:

The Lancet Gastroenterology and Hepatology